Pharmaceuticals firm to bring up to 85 new jobs to Salt Lake City

Shelton, Ryan
June 2009
Enterprise/Salt Lake City;6/1/2009, Vol. 38 Issue 49, p1
The article reports on the decision of Cephalon Inc., a pharmaceutical company based in Frazer, Pennsylvania, to relocate its subsidiary, CIMA Labs in Brooklyn Park, Minnesota to Salt Lake City, Utah. In line with the planned relocation, Cephalon has commenced the construction of the facility which will produce schedule II opoid pharmaceuticals. The relocation will cost Cephalon $16 million and will create 85 jobs.


Related Articles

  • Cima Leaves aaiPharma for Cephalon.  // Chemical Market Reporter;11/10/2003, Vol. 264 Issue 16, p2 

    Reports on the ownership and control of the drug delivery technology platform, Cima Labs Inc. won by drug company, Cephalon Inc. over aaiPharma Inc. Terms and details of the stock purchase; Operations and financial performance of the companies; Stock price.

  • Cephalon to acquire Cima Labs for $515 million.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p22 

    Reports on the plan of Cephalon Inc. to acquire Cima Labs Inc. in the U.S. Value of deal; Terms under the planned acquisition; Benefits of the acquisition for both companies.

  • Impax Laboratories initiates patent challenge relating to Generic Fentora.  // PharmaWatch: CNS;Jan2012, Vol. 11 Issue 1, p14 

    The article reports that Cephalon Inc. and CIMA Labs Inc. have filed a lawsuit against Impax Laboratories Inc. on November 18, 2011 for patent infringement with regards to the company's Fentora or fentanyl buccal tablets.

  • Cephalon Maintains CIMA Takeout Will Fly. Cohen, Judy Radler // Mergers & Acquisitions Report;4/12/2004, Vol. 17 Issue 15, p1 

    Discusses the status of the acquisition deal between Cephalon Inc. and CIMA Laboratories Inc. Amount of money involved in the deal; Tender offer of Cephalon Inc. for the shares of CIMA; Information on the two fentanyl products from CIMA Laboratories Inc. that Cephalon Inc. wants to acquire;...

  • Biotechnology News Round-up.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p2 

    Reports on developments related to the biotechnology industry in the U.S. as of December 2003. Efficacy of the drug ETC-216 of Esperion Therapeutics Inc.; Deal entered by AstraZeneca PLC with Abgenix Inc.; Agreement of Cephalon Inc. to acquire Cima Labs Inc.

  • SDC Worldwide Mergers & Acquisitions.  // Mergers & Acquisitions Report;9/8/2003, Vol. 16 Issue 34, p6 

    Provides an update on several merger and acquisition deals of companies worldwide as of September 8, 2003. CIMA Labs Inc. and Cephalon Inc.; JNI Corp. and Applied Micro Circuits Corp.; Jacksonville Bancorp and Franklin Bank Corp.

  • CIMA/aaiPharma Tie the Pharmaceutical Knot.  // High Yield Report;8/11/2003, Vol. 14 Issue 32, p1 

    Reports on the proposed merger between U.S.-based pharmaceutical companies aaiPharma and CIMA. Impact of the proposed merger on the financial conditions of the drug manufacturing industry; Estimated capital of the merged companies; Financial standings of the two pharmaceutical companies.

  • Pharma says acquisition is the right prescription. Speizer, Irwin // Business North Carolina;Oct2003, Vol. 23 Issue 10, p22 

    Reports on the merger of drug company aaiPharma Inc. with Cima Labs Inc. in 2003. Basis of the consolidation; Impact of the merger on the companies' stock performance; Changes after the merger.

  • FDA Approves Orally Dissolving Schizophrenia Drug.  // Chemical Market Reporter;3/15/2004, Vol. 265 Issue 11, p15 

    Reports on the U.S. Food and Drug Administration's approval of Alamo Pharmaceuticals' Fazaclo (clozapine), an oral drug for the treatment of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment. Cima Labs Inc.'s manufacture of the active ingredient for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics